Sodium-glucose cotransporter 2 inhibitors (SGLT2i) is a novelhypoglycemic agent, which have been shown to reduce cardiovascular death inpatients with diabetes mellitus (DM) [6, 7]. Here, SLC5A2 is linked to diabetes mellitus.